Verici Dx Plc Total Liabilities
Verici Dx Plc total liabilities. Based on the latest financial reports, Verici Dx Plc (VRCI) has total liabilities worth GBX2.06 Million GBX (≈ $251.01 USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See defensive interval ratio of Verici Dx Plc to measure how many days the company can operate on defensive assets alone.
Total Liabilities of Verici Dx Plc (2020–2024)
Total liabilities of Verici Dx Plc from 2020 to 2024. This chart illustrates how Verici Dx Plc's total liabilities have evolved over time, based on quarterly financial data.
Verici Dx Plc Competitors by Total Liabilities
The table below lists competitors of Verici Dx Plc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Athelney Trust plc
LSE:ATY
|
UK | GBX27.61K |
|
Jereissati Participações S.A.
SA:IGTI11
|
Brazil | R$4.79 Billion |
|
Argentex Group PLC
LSE:AGFX
|
UK | GBX113.40 Million |
|
Beowulf Mining
LSE:BEM
|
UK | GBX901.45K |
|
ADVFN Plc
LSE:AFN
|
UK | GBX1.35 Million |
|
Novae Group Plc
STU:NVAL
|
Germany | €463.03 Billion |
|
Fletcher King Plc
LSE:FLK
|
UK | GBX919.00K |
|
Epiminder Ltd
AU:EPI
|
Australia | AU$4.08 Million |
Liability Composition Analysis (2020–2024)
This chart breaks down Verici Dx Plc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see how large is Verici Dx Plc's balance sheet.
Liquidity & Leverage Metrics
Verici Dx Plc Total Liabilities Ratios Explained
Verici Dx Plc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.91 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.83 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.45 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Verici Dx Plc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Verici Dx Plc (2020–2024)
The table below shows the annual total liabilities of Verici Dx Plc from 2020 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | GBX2.23 Million ≈ $270.96 |
-42.68% |
| 2023-12-31 | GBX3.88 Million ≈ $472.69 |
+38.95% |
| 2022-12-31 | GBX2.80 Million ≈ $340.19 |
+54.98% |
| 2021-12-31 | GBX1.80 Million ≈ $219.51 |
+164.57% |
| 2020-12-31 | GBX681.89K ≈ $82.97 |
-- |
About Verici Dx Plc
Verici Dx plc, together with its subsidiary, Verici Dx Inc, develops prognostic and diagnostic tests for kidney transplant patients in the United Kingdom and the United States. The company develops Tutivia, a post-transplant diagnostic test focused on acute cellular rejection, including sub-clinical rejection; and Protega, a liquid biopsy to predict the risk of fibrosis and long-term graft failur… Read more